Dr Pavlina Spiliopoulou
- Clinical Senior Lecturer/Honorary Consultant in Medical Oncology (Clinical Research Garscube)
Research interests
Research groups
Publications
2025
Cartwright, Douglas, Kidd, Andrew C., Ansel, Sonam, Ascierto, Maria Libera and Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319
(2025)
Oncogenic signalling pathways in cancer immunotherapy: leader or
follower in this delicate dance?
International Journal of Molecular Sciences, 26(9),
4393.
(doi: 10.3390/ijms26094393)
(PMID:40362630)
(PMCID:PMC12072740)
Aalto, T. et al. (2025) The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: a pan-Canadian precision oncology initiative. Cancer Cell, 43(4), pp. 587-592. (doi: 10.1016/j.ccell.2025.03.014) (PMID:40185094)
2024
Genta, S. et al. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9(11), 103978. (doi: 10.1016/j.esmoop.2024.103978) (PMID:39549683) (PMCID:PMC11615122)
Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)
Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)
Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)
Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Kaur, Paramjit, Hammett, Tracey, Di Conza, Giusy and Lahn, Michael
(2024)
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers.
Cancer Drug Resistance, 7,
2.
(doi: 10.20517/cdr.2023.46)
(PMID:38318526)
(PMCID:PMC10838381)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Lopes, Carlos Diego Holanda and Spreafico, Anna
(2024)
Promising and minimally invasive biomarkers: targeting melanoma.
Cells, 13(1),
19.
(doi: 10.3390/cells13010019)
(PMID:38201222)
(PMCID:PMC10777980)
2023
Janse van Rensburg, Helena J., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Makhzoum, Anas and Healy, Brian D.
(2023)
Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery.
Case Reports in Oncology, 16(1),
pp. 662-669.
(doi: 10.1159/000532004)
(PMID:37933314)
(PMCID:PMC10625819)
Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)
Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)
Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Vornicova, Olga, Genta, Sofia and Spreafico, Anna
(2023)
Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers.
International Journal of Molecular Sciences, 24(2),
1294.
(doi: 10.3390/ijms24021294)
(PMID:36674809)
(PMCID:PMC9862040)
2022
Janse van Rensburg, Helena J., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Siu, Lillian L.
(2022)
Circulating biomarkers for therapeutic monitoring of anti-cancer agents.
Oncologist, 27(5),
pp. 352-362.
(doi: 10.1093/oncolo/oyac047)
(PMID:35285488)
(PMCID:PMC9074993)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Yang, S.Y. Cindy, Bruce, Jeff P., Wang, Ben X., Berman, Hal K., Pugh, Trevor J. and Siu, Lillian L.
(2022)
All is not lost: learning from 9p21 loss in cancer.
Trends in Immunology, 43(5),
pp. 379-390.
(doi: 10.1016/j.it.2022.03.003)
(PMID:35379580)
Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)
2021
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Hinsley, Samantha
ORCID: https://orcid.org/0000-0001-6903-4688, Mcneish, Iain A.
ORCID: https://orcid.org/0000-0002-9387-7586, Roxburgh, Patricia
ORCID: https://orcid.org/0000-0001-9869-591X and Glasspool, Rosalind
(2021)
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
International Journal of Gynecological Cancer, 31,
pp. 1037-1044.
(doi: 10.1136/ijgc-2021-002467)
(PMID:34016703)
2020
Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)
2019
MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)
2018
Fleming, Kathryn, McGuinness, James, Kipgen, David, Glen, Hilary and Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319
(2018)
A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer.
Case Reports in Oncological Medicine, 2018,
6927639.
(doi: 10.1155/2018/6927639)
(PMID:30402314)
(PMCID:PMC6192131)
Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)
2017
Graham, Janet, Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Arbuckle, Rob, Bridge, Julie Ann and Cassidy, James
(2017)
A pilot study of subjective well-being in colorectal cancer patients and their caregivers.
Patient Related Outcome Measures, 8,
pp. 111-119.
(doi: 10.2147/PROM.S141815)
(PMID:29089790)
(PMCID:PMC5656346)
2016
Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)
Bilsland, Alan E. ORCID: https://orcid.org/0000-0003-0957-3908, Spiliopoulou, Pavlina
ORCID: https://orcid.org/0000-0002-6486-6319 and Evans, T.R. Jeffry
ORCID: https://orcid.org/0000-0002-4175-914X
(2016)
Virotherapy: cancer gene therapy at last?
F1000Research, 5,
2105.
(doi: 10.12688/f1000research.8211.1)
(PMID:27635234)
(PMCID:PMC5007754)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Bowers, Sarah Pauline, Gibson, Sarah, White, Jeff and Reed, Nick
(2016)
Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics?
Scottish Medical Journal, 61(2),
pp. 111-116.
(doi: 10.1177/0036933016635409)
(PMID:27069005)
2015
Lemech, Charlotte, Dua, Divyanshu, Newmark, Joshua, Saggese, Matilde, Simmons, Emily, Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Arkenau, Hendrik-Tobias
(2015)
Patients' perceptions of research biopsies in Phase I Oncology Trials.
Oncology, 88(2),
pp. 95-102.
(doi: 10.1159/000368161)
(PMID:25322682)
Lindsay, Colin R., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Waterston, Ashita
(2015)
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.
Therapeutic Advances in Medical Oncology, 7(2),
pp. 107-121.
(doi: 10.1177/1758834014566619)
(PMID:25755683)
(PMCID:PMC4346213)
2014
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Arkenau, Hendrik-Tobias
(2014)
Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies.
World Journal of Gastroenterology, 20(30),
pp. 10288-10295.
(doi: 10.3748/wjg.v20.i30.10288)
(PMID:25132745)
(PMCID:PMC4130836)
2011
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Panwar, Udaiveer and Davidson, Neville
(2011)
Rectal small cell carcinoma: A case report and review of the literature.
Case Reports in Oncology, 4(3),
pp. 475-480.
(doi: 10.1159/000332760)
(PMID:22114573)
(PMCID:PMC3220900)
Articles
Cartwright, Douglas, Kidd, Andrew C., Ansel, Sonam, Ascierto, Maria Libera and Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319
(2025)
Oncogenic signalling pathways in cancer immunotherapy: leader or
follower in this delicate dance?
International Journal of Molecular Sciences, 26(9),
4393.
(doi: 10.3390/ijms26094393)
(PMID:40362630)
(PMCID:PMC12072740)
Aalto, T. et al. (2025) The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: a pan-Canadian precision oncology initiative. Cancer Cell, 43(4), pp. 587-592. (doi: 10.1016/j.ccell.2025.03.014) (PMID:40185094)
Genta, S. et al. (2024) Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients. ESMO Open, 9(11), 103978. (doi: 10.1016/j.esmoop.2024.103978) (PMID:39549683) (PMCID:PMC11615122)
Spear, S. et al. (2024) PTEN loss shapes macrophage dynamics in high grade serous ovarian carcinoma. Cancer Research, (doi: 10.1158/0008-5472.can-23-3890) (PMID:39186679) (PMCID:PMC7616669) (In Press)
Manchanda, R. et al. (2024) Cost-effectiveness of unselected multigene germline and somatic genetic testing for epithelial ovarian cancer. Journal of the National Comprehensive Cancer Network, 22(2D), e237331. (doi: 10.6004/jnccn.2023.7331) (PMID:38866043)
Spiliopoulou, P. et al. (2024) A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301). Journal of Experimental and Clinical Cancer Research, 43(1), 100. (doi: 10.1186/s13046-024-03010-1) (PMID:38566164) (PMCID:PMC10986017)
Lee, C. L. et al. (2024) Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential biomarker for isocitrate dehydrogenase (IDH1/2) mutant cholangiocarcinoma. Molecular Cancer Therapeutics, 23(3), pp. 394-399. (doi: 10.1158/1535-7163.mct-23-0460) (PMID:38015561) (PMCID:PMC10911702)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Kaur, Paramjit, Hammett, Tracey, Di Conza, Giusy and Lahn, Michael
(2024)
Targeting T regulatory (Treg) cells in immunotherapy-resistant cancers.
Cancer Drug Resistance, 7,
2.
(doi: 10.20517/cdr.2023.46)
(PMID:38318526)
(PMCID:PMC10838381)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Lopes, Carlos Diego Holanda and Spreafico, Anna
(2024)
Promising and minimally invasive biomarkers: targeting melanoma.
Cells, 13(1),
19.
(doi: 10.3390/cells13010019)
(PMID:38201222)
(PMCID:PMC10777980)
Janse van Rensburg, Helena J., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Makhzoum, Anas and Healy, Brian D.
(2023)
Remitting seronegative symmetrical synovitis with pitting edema: a case report of an immune-related adverse event following surgery.
Case Reports in Oncology, 16(1),
pp. 662-669.
(doi: 10.1159/000532004)
(PMID:37933314)
(PMCID:PMC10625819)
Genta, S. et al. (2023) Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT). Journal of Experimental and Clinical Cancer Research, 42(1), 276. (doi: 10.1186/s13046-023-02851-6) (PMID:37865776) (PMCID:PMC10589949)
Mittal, A. et al. (2023) The role of cytoreductive nephrectomy and systemic therapy in the management of tumour thrombus in patients with metastatic renal cell carcinoma. British Journal of Cancer, 128(10), pp. 1888-1896. (doi: 10.1038/s41416-023-02166-5) (PMID:36859686) (PMCID:PMC10147707)
Spiliopoulou, P. et al. (2023) Longitudinal efficacy and toxicity of SARS-CoV-2 vaccination in cancer patients treated with immunotherapy. Cell Death and Disease, 14(1), 49. (doi: 10.1038/s41419-022-05548-4) (PMID:36670100) (PMCID:PMC9853486)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Vornicova, Olga, Genta, Sofia and Spreafico, Anna
(2023)
Shaping the future of immunotherapy targets and biomarkers in melanoma and non-melanoma cutaneous cancers.
International Journal of Molecular Sciences, 24(2),
1294.
(doi: 10.3390/ijms24021294)
(PMID:36674809)
(PMCID:PMC9862040)
Janse van Rensburg, Helena J., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Siu, Lillian L.
(2022)
Circulating biomarkers for therapeutic monitoring of anti-cancer agents.
Oncologist, 27(5),
pp. 352-362.
(doi: 10.1093/oncolo/oyac047)
(PMID:35285488)
(PMCID:PMC9074993)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Yang, S.Y. Cindy, Bruce, Jeff P., Wang, Ben X., Berman, Hal K., Pugh, Trevor J. and Siu, Lillian L.
(2022)
All is not lost: learning from 9p21 loss in cancer.
Trends in Immunology, 43(5),
pp. 379-390.
(doi: 10.1016/j.it.2022.03.003)
(PMID:35379580)
Spiliopoulou, P. et al. (2022) Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma. Molecular Cancer Therapeutics, 21(4), pp. 522-534. (doi: 10.1158/1535-7163.MCT-21-0743) (PMID:35131874) (PMCID:PMC9377747)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Hinsley, Samantha
ORCID: https://orcid.org/0000-0001-6903-4688, Mcneish, Iain A.
ORCID: https://orcid.org/0000-0002-9387-7586, Roxburgh, Patricia
ORCID: https://orcid.org/0000-0001-9869-591X and Glasspool, Rosalind
(2021)
Metronomic oral cyclophosphamide in relapsed ovarian cancer.
International Journal of Gynecological Cancer, 31,
pp. 1037-1044.
(doi: 10.1136/ijgc-2021-002467)
(PMID:34016703)
Leung, E. Y.L. et al. (2020) NK cells augment oncolytic adenovirus cytotoxicity in ovarian cancer. Molecular Therapy - Oncolytics, 16, pp. 289-301. (doi: 10.1016/j.omto.2020.02.001) (PMID:32195317) (PMCID:PMC7068056)
MacPherson, I. R. et al. (2019) A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer. Breast Cancer Research, 22, 1. (doi: 10.1186/s13058-019-1178-0) (PMID:31892325) (PMCID:PMC6938617)
Fleming, Kathryn, McGuinness, James, Kipgen, David, Glen, Hilary and Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319
(2018)
A case of Lenvatinib-induced Focal Segmental Glomerulosclerosis (FSGS) in metastatic medullary thyroid cancer.
Case Reports in Oncological Medicine, 2018,
6927639.
(doi: 10.1155/2018/6927639)
(PMID:30402314)
(PMCID:PMC6192131)
Rust, K. et al. (2018) Routine germline BRCA1 and BRCA2 testing in ovarian carcinoma patients: analysis of the Scottish real life experience. BJOG: An International Journal of Obstetrics and Gynaecology, 125(11), pp. 1451-1458. (doi: 10.1111/1471-0528.15171) (PMID:29460478)
Graham, Janet, Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Arbuckle, Rob, Bridge, Julie Ann and Cassidy, James
(2017)
A pilot study of subjective well-being in colorectal cancer patients and their caregivers.
Patient Related Outcome Measures, 8,
pp. 111-119.
(doi: 10.2147/PROM.S141815)
(PMID:29089790)
(PMCID:PMC5656346)
Sharma, P. et al. (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncology, 17(11), pp. 1590-1598. (doi: 10.1016/S1470-2045(16)30496-X) (PMID:27733243) (PMCID:PMC5648054)
Bilsland, Alan E. ORCID: https://orcid.org/0000-0003-0957-3908, Spiliopoulou, Pavlina
ORCID: https://orcid.org/0000-0002-6486-6319 and Evans, T.R. Jeffry
ORCID: https://orcid.org/0000-0002-4175-914X
(2016)
Virotherapy: cancer gene therapy at last?
F1000Research, 5,
2105.
(doi: 10.12688/f1000research.8211.1)
(PMID:27635234)
(PMCID:PMC5007754)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Bowers, Sarah Pauline, Gibson, Sarah, White, Jeff and Reed, Nick
(2016)
Three cases of thyroid cancer following the diagnosis of testicular cancer: treatment-related complication or genetics?
Scottish Medical Journal, 61(2),
pp. 111-116.
(doi: 10.1177/0036933016635409)
(PMID:27069005)
Lemech, Charlotte, Dua, Divyanshu, Newmark, Joshua, Saggese, Matilde, Simmons, Emily, Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Arkenau, Hendrik-Tobias
(2015)
Patients' perceptions of research biopsies in Phase I Oncology Trials.
Oncology, 88(2),
pp. 95-102.
(doi: 10.1159/000368161)
(PMID:25322682)
Lindsay, Colin R., Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Waterston, Ashita
(2015)
Blinded by the light: why the treatment of metastatic melanoma has created a new paradigm for the management of cancer.
Therapeutic Advances in Medical Oncology, 7(2),
pp. 107-121.
(doi: 10.1177/1758834014566619)
(PMID:25755683)
(PMCID:PMC4346213)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319 and Arkenau, Hendrik-Tobias
(2014)
Rationally designed treatment for metastatic colorectal cancer: Current drug development strategies.
World Journal of Gastroenterology, 20(30),
pp. 10288-10295.
(doi: 10.3748/wjg.v20.i30.10288)
(PMID:25132745)
(PMCID:PMC4130836)
Spiliopoulou, Pavlina ORCID: https://orcid.org/0000-0002-6486-6319, Panwar, Udaiveer and Davidson, Neville
(2011)
Rectal small cell carcinoma: A case report and review of the literature.
Case Reports in Oncology, 4(3),
pp. 475-480.
(doi: 10.1159/000332760)
(PMID:22114573)
(PMCID:PMC3220900)